Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.54 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PI4KA | P42356 | 1/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.40 |
| ▸ | SMAD2 | Q15796 | 1/20 | 0.40 |
| ▸ | VRK1 | Q99986 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
| ▸ | PFKFB3 | Q16875 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20658696 | 0.82 | DYRK1A (0.52) | DYRK1AADORA2ATGFBR1RIPK1MAPK14 | |
| SCHEMBL20667098 | 0.81 | DYRK1A (0.58) | DYRK1AADORA2ATGFBR1RIPK1PIK3CA | |
| SCHEMBL20667135 | 0.79 | ADORA2A (0.57) | ADORA2AADORA1 | |
| SCHEMBL20658510 | 0.79 | DYRK1A (0.49) | DYRK1AADORA2ATGFBR1RIPK1MAPK14 | |
| SCHEMBL20658558 | 0.78 | ADORA2A (0.59) | ADORA2ATGFBR1MAPK14PIK3CAKMT2A | |
| SCHEMBL2031287 | 0.78 | ADORA2A (0.64) | ADORA2AKMT2AATMTLR9ALDH1A1 | |
| SCHEMBL29678556 | 0.78 | ADORA2A (0.64) | ADORA2AKMT2AATMTLR9ALDH1A1 | |
| SCHEMBL6032917 | 0.76 | DYRK1A (0.62) | DYRK1ATGFBR1RIPK1MAPK14PIK3CA | |
| SCHEMBL20658540 | 0.76 | ADORA2A (0.63) | ADORA2APIK3CAKMT2AALDH1A1HSD17B10 | |
| SCHEMBL20658453 | 0.76 | ADORA2A (0.67) | DYRK1AADORA2ATGFBR1PIK3CAPI4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | NUVATION BIO INC (US) | 2021-09-23 | — | — | US | disclosed |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | NUVATION BIO INC (US) | 2021-09-23 | — | — | US | disclosed |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | NUVATION BIO INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | NUVATION BIO INC. (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3654978-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | Nuvation Bio Inc. (US) | 2020-05-27 | — | — | EP | disclosed |
| CN-111163780-A | Heterocyclic compounds as adenosine antagonists | 诺维逊生物股份有限公司 | 2020-05-15 | — | — | CN | disclosed |
| WO-2019018584-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | GiraFpharma LLC (US) | 2019-01-24 | — | — | WO | disclosed |
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-01-24 | — | — | US | disclosed |
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | DYRK1A 3065/4885ADORA2A 1/4885TGFBR1 2712/4885 |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | ADORA2A, ADORA3, ADORA1 | DYRK1A 3065/4885ADORA2A 1/4885TGFBR1 2712/4885 |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | DYRK1A 3065/4885ADORA2A 1/4885TGFBR1 2712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.